Work

ED Use of Extended-Release 7-Day Injectable Buprenorphine for Minimal Opioid Withdrawal

Year: 2025

Type: article

Source: Drug and Alcohol Dependence

DOI: 10.1016/j.drugalcdep.2024.112200

Authors: D'Onofrio, Andrew A Herring, Jeanmarie Perrone, Kathryn Hawk, Elizabeth Samuels, Ethan Cowan, Erik Anderson, Ryan McCormack, Kristin Huntley, Patricia Owens, Shara Martel, Mark Schactman, Michelle Lofwall, Sharon Walsh, James Dziura, David Fiellin

Institutions: Yale University, Alameda Health System, Highland Hospital, University of Pennsylvania, University of California, Los Angeles, Icahn School of Medicine at Mount Sinai, NYU Langone Health, New York University, National Institute on Drug Abuse, Emmes (United States), University of Kentucky

Language: English

Topic: Opioid Use Disorder Treatment

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: National Institutes of Health, National Institute on Drug Abuse

Awards: G9000113508, NIDA Clinical Trials Network: New York Node - Renewal-GY24

OpenAlex ID: W4407076042

FWCI:

Cites:

Cited by:

Related to: 10